Should I buy or sell Lyra Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LYRA shares. View LYRA analyst ratings or view top-rated stocks .

What is Lyra Therapeutics' stock price target for 2024?

4 brokers have issued 12 month price objectives for Lyra Therapeutics' stock. Their LYRA share price targets range from $11.00 to $15.00. On average, they expect the company's share price to reach $12.67 in the next twelve months. This suggests a possible upside of 135.0% from the stock's current price. View analysts price targets for LYRA or view top-rated stocks among Wall Street analysts .

How have LYRA shares performed in 2024?

Lyra Therapeutics' stock was trading at $5.24 on January 1st, 2024. Since then, LYRA shares have increased by 2.9% and is now trading at $5.39. View the best growth stocks for 2024 here .

When is Lyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our LYRA earnings forecast .

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) released its earnings results on Thursday, March, 21st. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.11. The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.52 million. Lyra Therapeutics had a negative trailing twelve-month return on equity of 72.62% and a negative net margin of 4,023.11%.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE) , DocuSign (DOCU) , Intel (INTC) , OPKO Health (OPK) , Valero Energy (VLO) , Advanced Micro Devices (AMD) , CrowdStrike (CRWD) , Gilead Sciences (GILD) , Micron Technology (MU) and ONEOK (OKE) .

When did Lyra Therapeutics IPO?

Lyra Therapeutics (LYRA) raised $52 million in an IPO on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LYRA

Lyra Therapeutics (LYRA) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free LYRA Stock Alerts

$5.39

-0.02 (-0.37%)

(As of 04/18/2024 ET)

Compare

Today's Range: $5.21
▼
$5.52
50-Day Range: $4.82
▼
$6.53
52-Week Range: $1.93
▼
$6.79

Volume: 387,833 shs
Average Volume: 321,122 shs
Market Capitalization: $322.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.67

Get Lyra Therapeutics alerts:

Lyra Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 135.0% Upside
$12.67 Price Target
Short Interest: Healthy
0.37% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.04) to ($1.17) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.63 out of 5 stars

Medical Sector

641st out of 918 stocks

Surgical & Medical Instruments Industry

67th out of 91 stocks

3.5

Analyst's Opinion

Consensus Rating
Lyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Lyra Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.37% of the outstanding shares of Lyra Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Lyra Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Lyra Therapeutics has recently increased by 8.10%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Lyra Therapeutics does not currently pay a dividend.
Dividend Growth
Lyra Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LYRA.

1.1

News and Social Media Coverage

Search Interest
18 people have searched for LYRA on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
MarketBeat Follows
4 people have added Lyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.42% of the stock of Lyra Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Lyra Therapeutics are expected to decrease in the coming year, from ($1.04) to ($1.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lyra Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lyra Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lyra Therapeutics has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Lyra Therapeutics Stock (NASDAQ:LYRA)

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

LYRA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LYRA Stock News Headlines

March 26, 2024 | finance.yahoo.com

Private equity firms who hold 39% of Lyra Therapeutics, Inc. (NASDAQ:LYRA) gained 6.8%, institutions profited as well

March 23, 2024 | finance.yahoo.com

Lyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS Projections

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 22, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Lyra Therapeutics’ LYR-210 Amidst Phase 3 Trial and Market Opportunity

March 22, 2024 | msn.com

Lyra Therapeutics files for $300M mixed shelf

March 21, 2024 | globenewswire.com

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 15, 2024 | finance.yahoo.com

LYRA Jul 2024 2.500 call

March 15, 2024 | finance.yahoo.com

LYRA Jul 2024 7.500 call

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 15, 2024 | finance.yahoo.com

LYRA Apr 2024 7.500 put

March 15, 2024 | finance.yahoo.com

LYRA May 2024 7.500 call

March 1, 2024 | globenewswire.com

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 21, 2024 | finance.yahoo.com

Here's What Could Help Lyra Therapeutics, Inc. (LYRA) Maintain Its Recent Price Strength

February 12, 2024 | bizjournals.com

Lyra Therapeutics invests in Mass. manufacturing with new HQ

January 29, 2024 | businessinsider.com

These are the 7 healthcare startups primed to IPO when the market reopens

January 28, 2024 | msn.com

15 Unhappiest States in the US

January 17, 2024 | finance.yahoo.com

What Makes Lyra Therapeutics, Inc. (LYRA) a Good Fit for 'Trend Investing'

December 27, 2023 | benzinga.com

Lyra Therapeutics Stock (NASDAQ:LYRA) Dividends: History, Yield and Dates

November 15, 2023 | finance.yahoo.com

Executive Chairman of Lyra Therapeutics Harlan Waksal Buys 11% More Shares

November 15, 2023 | finance.yahoo.com

Lyra Therapeutics Insider Ups Holding By 11% During Year

November 14, 2023 | benzinga.com

Executive Chair of Lyra Therapeutics Purchased $74K In Stock

November 11, 2023 | benzinga.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Lyra Therapeutics, Inc. (NASDAQ: LYRA) and Encourages Investors to Contact the Firm

November 7, 2023 | msn.com

Lyra Therapeutics GAAP EPS of -$0.27, revenue of $544M

November 7, 2023 | finance.yahoo.com

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

October 16, 2023 | benzinga.com

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

October 16, 2023 | finance.yahoo.com

Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer

October 11, 2023 | finance.yahoo.com

Lyra Therapeutics, Inc.'s (NASDAQ:LYRA) market cap dropped US$20m last week; Private equity firms bore the brunt

See More Headlines

Receive LYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:LYRA
CUSIP: N/A
CIK: 1327273
Web: www.lyratherapeutics.com
Phone: 617-393-4600
Fax: N/A
Employees: 88
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.67
High Stock Price Target: $15.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +135.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-62,680,000.00
Net Margins: -4,023.11%
Pretax Margin: -4,019.32%
Return on Equity: -72.62%
Return on Assets: -50.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.35
Quick Ratio: 5.35

Sales & Book Value

Annual Sales: $1.56 million
Price / Sales: 206.41
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.56 per share
Price / Book: 3.46

Miscellaneous

Outstanding Shares: 59,740,000
Free Float: 49,336,000
Market Cap: $322.00 million
Optionable: Optionable
Beta: 0.23

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Harlan W. Waksal M.D. (Age 71)
Executive Chairman
Comp: $210.06k
Dr. Maria Palasis Ph.D. (Age 59)
CEO, President & Director
Comp: $942.7k
Dr. John E. Bishop Ph.D. (Age 62)
Chief Technology Officer
Comp: $662.9k
Dr. Carmichael S. Roberts Jr. (Age 56)
Ph.D., Co-Founder
Mr. Jason Cavalier (Age 51)
CFO, Treasurer & Secretary
Comp: $464.11k
Mr. Ray Knox
Vice President of Operations
Ms. Ellen Cavaleri
Senior Vice President of Investor Relations & Communications
Mr. Ronan P. O'Brien J.D. (Age 51)
Chief Legal Officer
Ms. Corinne Noyes (Age 56)
Senior Vice President of Commercial Strategy & Market Development
Comp: $426.73k
Ms. Vineeta Belanger Ph.D.
Senior Vice President of Clinical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LYRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Lyra Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LYRA shares.
View LYRA analyst ratings or view top-rated stocks.
What is Lyra Therapeutics' stock price target for 2024?: 4 brokers have issued 12 month price objectives for Lyra Therapeutics' stock. Their LYRA share price targets range from $11.00 to $15.00. On average, they expect the company's share price to reach $12.67 in the next twelve months. This suggests a possible upside of 135.0% from the stock's current price.
View analysts price targets for LYRA or view top-rated stocks among Wall Street analysts.
How have LYRA shares performed in 2024?: Lyra Therapeutics' stock was trading at $5.24 on January 1st, 2024. Since then, LYRA shares have increased by 2.9% and is now trading at $5.39.
View the best growth stocks for 2024 here.
When is Lyra Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our LYRA earnings forecast.

How were Lyra Therapeutics' earnings last quarter?: Lyra Therapeutics, Inc. (NASDAQ:LYRA) released its earnings results on Thursday, March, 21st. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.11. The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.52 million. Lyra Therapeutics had a negative trailing twelve-month return on equity of 72.62% and a negative net margin of 4,023.11%.
What other stocks do shareholders of Lyra Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE).
When did Lyra Therapeutics IPO?: Lyra Therapeutics (LYRA) raised $52 million in an IPO on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager.
How do I buy shares of Lyra Therapeutics?: Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LYRA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lyra Therapeutics (LYRA) Stock Price, News & Analysis

Lyra Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Lyra Therapeutics Stock (NASDAQ:LYRA)

LYRA Stock Price History

LYRA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

LYRA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™